Your browser doesn't support javascript.
loading
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
Kersting, Sabina; Dubois, Julie; Nasserinejad, Kazem; Dobber, Johan A; Mellink, Clemens; van der Kevie-Kersemaekers, Anne-Marie F; Evers, Ludo M; de Boer, Fransien; Koene, Harry R; Schreurs, John; van der Klift, Marjolein; Velders, Gerjo A; van der Spek, Ellen; van der Straaten, Hanneke M; Hoogendoorn, Mels; van Gelder, Michel; Posthuma, Eduardus F M; Visser, Hein P J; Houtenbos, Ilse; Idink, Cecile A M; Issa, Djamila E; Dompeling, Ellen C; van Zaanen, Henk C T; Veelken, Hendrik; Levenga, Henriette; Tick, Lidwine W; Terpstra, Wim E; Tonino, Sanne H; Boyer, Michelle; Mobasher, Mehrdad; Levin, Mark-David; Kater, Arnon P.
  • Kersting S; Department of Hematology, HAGA Teaching Hospital, The Hague, Netherlands. Electronic address: s.kersting@hagaziekenhuis.nl.
  • Dubois J; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, Netherlands.
  • Nasserinejad K; Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Dobber JA; Department of Laboratory Special Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands.
  • Mellink C; Department of Human Genetics, Section Cytogenetics, Amsterdam University Medical Center, Amsterdam, Netherlands.
  • van der Kevie-Kersemaekers AF; Department of Human Genetics, Section Cytogenetics, Amsterdam University Medical Center, Amsterdam, Netherlands.
  • Evers LM; Department of Laboratory Special Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands.
  • de Boer F; Department of Internal Medicine, Ikazia Hospital, Rotterdam, Netherlands.
  • Koene HR; Department of Hematology, Antonius Hospital, Nieuwegein, Netherlands.
  • Schreurs J; Department of Internal Medicine, Martini Hospital, Groningen, Netherlands.
  • van der Klift M; Department of Internal Medicine, Amphia Hospital, Breda, Netherlands.
  • Velders GA; Department of Internal Medicine, Gelderland Valley Hospital, Ede, Netherlands.
  • van der Spek E; Department of Internal Medicine, Rijnstate Hospital, Arnhem, Netherlands.
  • van der Straaten HM; Department of Internal Medicine, St Jansdal Hospital, Harderwijk, Netherlands.
  • Hoogendoorn M; Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, Netherlands.
  • van Gelder M; Department of Hematology, MUMC, Maastricht, Netherlands.
  • Posthuma EFM; Department of Internal Medicine, RDGG, Delft, Netherlands.
  • Visser HPJ; Department of Internal Medicine, Northwest Clinics, Alkmaar, Netherlands.
  • Houtenbos I; Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, Netherlands.
  • Idink CAM; Department of Internal Medicine, ZorgSaam hospital, Terneuzen, Netherlands.
  • Issa DE; Department of Internal Medicine, Jeroen Bosch hospital, 's-Hertogenbosch, Netherlands.
  • Dompeling EC; Department of Hematology, Isala Hospital, Zwolle, Netherlands.
  • van Zaanen HCT; Department of Internal Medicine, St Franciscus Hospital, Rotterdam, Netherlands.
  • Veelken H; Department of Hematology, LUMC, Leiden, Netherlands.
  • Levenga H; Department of Internal Medicine, Groene Harthospital, Gouda, Netherlands.
  • Tick LW; Department of Internal Medicine, Maxima MC, Eindhoven, Netherlands.
  • Terpstra WE; Department of Internal Medicine, OLVG, Amsterdam, Netherlands.
  • Tonino SH; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, Netherlands.
  • Boyer M; Roche Products Limited, Welwyn Garden City, UK.
  • Mobasher M; Genentech, South San Francisco, CA, USA.
  • Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, Netherlands.
  • Kater AP; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, Netherlands.
Lancet Haematol ; 9(3): e190-e199, 2022 Mar.
Article en En | MEDLINE | ID: mdl-35240075
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B Tipo de estudio: Clinical_trials Límite: Adolescent / Female / Humans / Male Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B Tipo de estudio: Clinical_trials Límite: Adolescent / Female / Humans / Male Idioma: En Año: 2022 Tipo del documento: Article